Vaxcyte Inc. (PCVX) Director Owns Stock Worth $335.0

0
67
DASH
DASH

Vaxcyte Inc. (NASDAQ:PCVX) finished Friday with an addition of $0.53 to close at $47.95, an upside of 1.12 percent. An average of 694,500 shares of common stock have been traded in the last five days. There was a gain of $0.30 in the past week, and it reached a new high 23 times over the past 12 months. The last 20 days have seen an average of 880,520 shares traded, while the 50-day average volume stands at 1,537,196.

PCVX stock has increased by 4.10% in the last month. The company shares reached their 1-month lowest point of $41.14 on 12/07/22. With the stock rallying to its 52-week high on 12/23/22, shares of the company touched a low of $16.78 and a high of $48.19 in 52 weeks. It has reached a new high 22 times so far this year and achieved 101.56% or $24.16 in price. In spite of this, the price is down -0.50% from the 52-week high.


Will You Miss Out On This Growth Stock Boom?

A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.

And this is just one of our 5 Best Growth Stocks To Own For 2023.

Sponsored


Insider Transactions

PCVX stock investors should be aware that Vaxcyte Inc. (PCVX) stock had its last reported insider trading activity 19 days ago on Dec 12. In this transaction, the insider spent $14,717. Director, Lukatch Heath, disposed of 4,335 shares at a price of $46.13 on Nov 10. The insider now owns more than $199,989 worth of shares. Prior to that, Director Lukatch Heath went on to Sale 4,000 shares at $38.25 each on Oct 26. An amount of $153,000 was transacted.

Financial Health

The quick ratio of Vaxcyte Inc. for the three months ended June 29 was 9.40, and the current ratio was 9.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Its gross profit as reported stood at $7000.0 compared to revenue of $103.67 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Vaxcyte Inc.’s return on assets was -44.90%.

Earnings Surprise

For the three-month period that ended June 29, Vaxcyte Inc. had $83.83 million in cash. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$57.92 million in the quarter, while revenues of -$48.53 million were grew 54.04%. The analyst consensus anticipated Vaxcyte Inc.’s latest quarter earnings to come in at -$0.69 per share, but it turned out to be -$0.8, a -15.90% surprise. For the quarter, EBITDA amounted to -$56.46 million. Shareholders own equity worth $78.98 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Vaxcyte Inc. (PCVX) price momentum. RSI 9-day as of the close on 30 December was 63.02%, suggesting the stock is Neutral, with historical volatility in this time frame at 53.79%.

As of today, PCVX’s price is $46.73 +0.63% or $0.30 from its 5-day moving average. PCVX is currently trading +5.38% higher than its 20-day SMA and +84.21% higher than its 100-day SMA. However, the stock’s current price level is +111.89% above the SMA50 and +82.60% above the SMA200.

The stochastic %K and %D were 82.99% and 74.21%, respectively, and the average true range (ATR) was 2.02. With the 14-day stochastic at 95.82% and the average true range at 2.08, the RSI (14) stands at 61.76%. The stock has reached 1.01 on the 9-day MACD Oscillator while the 14-day reading was at 1.32.

Analyst Ratings

Guggenheim launched coverage on Vaxcyte Inc. (NASDAQ: PCVX) in its analyst report released on December 15, 2022. The firm assigned the stock a Buy rating. The consensus rating for Vaxcyte Inc. (PCVX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell PCVX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 8 others rate it as a “buy”.

What is PCVX’s price target for the next 12 months?

Analysts predict a range of price targets between $52.00 and $70.00, with a median target of $64.00. Taking a look at these predictions, the average price target given by analysts for Vaxcyte Inc. (PCVX) stock is $62.43.

LEAVE A REPLY

Please enter your comment!
Please enter your name here